Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial (vol 22, 205, 2022)

被引：0
|
作者：
Ailani, Jessica [1 ]
Mcallister, Peter [2 ]
Winner, Paul K. [3 ]
Chakhava, George [4 ]
Josiassen, Mette Krog [5 ]
Lindsten, Annika [5 ]
Sperling, Bjorn [5 ]
Ettrup, Anders [5 ]
Cady, Roger [6 ,7 ]
机构：
[1] Georgetown Univ Hosp, Dept Neurol, Washington, DC USA
[2] New England Inst Neurol & Headache, Stamford, CT USA
[3] Palm Beach Headache Ctr, W Palm Beach, FL USA
[4] DTvildiani Med Univ, Multiprofile Clin Consilium Medulla, Georgian Assoc Med Specialties, Tbilisi, Georgia
[5] H Lundbeck A S, Copenhagen, Denmark
[6] Lundbeck LLC, Deerfield, IL 60015 USA
[7] RK Consults, Ozark, MO 65721 USA
来源：
BMC NEUROLOGY | 2023年 / 23卷 / 01期
关键词：
D O I：
10.1186/s12883-023-03368-3
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 25 条
  • [21] Efficacy and Tolerability of Rizatriptan for Treatment of a Single Migraine Attack in Pediatric Migraineurs: Results from a Randomized, Double-Blind, Placebo-Controlled Trial Using a Novel Enrichment Design
    Hewitt, D. J.
    Pearlman, E.
    Lewis, D.
    Hamalainen, M.
    Connor, K.
    Michelson, D.
    Zhang, Y.
    Mozley, Harper L.
    N, Strickler
    Bachman, R.
    Mahoney, E.
    Lines, C.
    Ho, T. W.
    HEADACHE, 2012, 52 (05): : 885 - 886
  • [22] Efficacy and Tolerability of Rizatriptan for Treatment of a Single Migraine Attack in Pediatric Migraineurs: Results from a Randomized, Double-Blind, Placebo-Controlled Trial Using a Novel Enrichment Design
    Ho, Tony
    Pearlman, Eric
    Lewis, Donald
    Hamalainen, Mirja
    Connor, Kathryn
    Michelson, David
    Zhang, Ying
    Harper-Mozley, Lyn
    Strickler, Nancy
    Bachman, Robert
    Mahoney, Erin
    Lines, Christopher
    Hewitt, David
    NEUROLOGY, 2012, 78
  • [23] Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies (vol 22, 141, 2021)
    Nahas, Stephanie J.
    Naegel, Steffen
    Cohen, Joshua M.
    Ning, Xiaoping
    Janka, Lindsay
    Campos, Verena Ramirez
    Krasenbaum, Lynda J.
    Holle-Lee, Dagny
    Kudrow, David
    Lampl, Christian
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [24] RAPID RECURRENCE OF SYMPTOMS, ENDOSCOPIC FINDINGS, AND ESOPHAGEAL EOSINOPHILIA WITHOUT MAINTENANCE THEARPY AFTER SUCCESSFUL INITIAL TREATMENT: RESULTS FROM THE OBSERVATION PHASE OF A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY CLINICAL TRIAL
    Dellon, Evan S.
    Woosley, John T.
    Arrington, Ashley
    McGee, Sarah J.
    Covington, Jacquelyn
    Moist, Susan E.
    Gebhart, Jessica H.
    Martin, Christopher
    Galanko, Joseph
    Baron, John A.
    Shaheen, Nicholas J.
    GASTROENTEROLOGY, 2019, 156 (06) : S713 - S714
  • [25] Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER) (Jan, 10.1007/s40261-021-01115-5, 2022)
    Tepper, Stewart J.
    Ailani, Jessica
    Ford, Janet H.
    Nichols, Russell M.
    Li, Lily Q.
    Kemmer, Phebe
    Hand, Austin L.
    Tockhorn-Heidenreich, Antje
    CLINICAL DRUG INVESTIGATION, 2022, 42 (03) : 277 - 277
123